Cogent Biosciences, Inc.
COGT
Updated: 24/09/2026, 17:02:26
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
No summaries found.
- Share price
- $30.95
- Market cap
- $5.29B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Andrew R. Robbins
- Employees
- 258
- IPO date
- 29/03/2018
- Beta
- 0.307
- Last dividend
- $0.00
- Day range
- $30.78 – $31.28
- 52-week range
- $12.97 – $43.73
- 1-day performance
- -1.48%
- 1-year performance
- 138.59%
- Current drawdown (1Y)
- -29.24%
- CIK
- 0001622229
- CUSIP
- 19240Q201
- ISIN
- US19240Q2012
- Created
- 07/12/2025, 03:24:08
- Last update
- 24/09/2026, 17:02:26
Track Cogent Biosciences, Inc. with an AI analyst
See which prediction-market events move COGT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
Seeking Alpha • STOCK • 14/06/2026, 11:13:38
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
GlobeNewsWire • STOCK • 12/06/2026, 10:01:00
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
GlobeNewsWire • STOCK • 12/06/2026, 10:00:00
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Globe News Wire • STOCK • 30/05/2026, 10:00:00
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
GlobeNewsWire • STOCK • 12/05/2026, 11:30:00
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
GlobeNewsWire • STOCK • 05/05/2026, 10:00:00
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
GlobeNewsWire • STOCK • 17/04/2026, 10:00:00
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'
Seeking Alpha • STOCK • 02/04/2026, 15:16:11
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
GlobeNewsWire • STOCK • 01/04/2026, 10:00:00
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
The Motley Fool • STOCK • 21/03/2026, 20:13:55
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
The Motley Fool • STOCK • 21/03/2026, 19:23:15
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Zacks Investment Research • STOCK • 17/03/2026, 13:40:49